SC
NEUP

Shay Capital’s Neuphoria Therapeutics NEUP Stock Holding History

Shay Capital’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$615K Sell
151,010
-18,049
-11% -$76.3K 0.05% 230
2025
Q4 		$656K Buy
+169,059
New +$1.2M 0.07% 239

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Shay Capital's NEUP Position: Q1 2026 in Review

Shay Capital reduced its Neuphoria Therapeutics (NEUP) stake by 11% in Q1 2026, selling an estimated $76.3K and leaving 151,010 shares worth $615K. The position accounts for 0.05% of the portfolio, ranked #230.

Shay Capital first reported a position in NEUP in Q4 2025 and has held it in 2 quarters since. The position peaked at $656K in Q4 2025. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Shay Capital held 151,010 shares of Neuphoria Therapeutics worth $615K as of Q1 2026.
  • Shay Capital sold 18,049 Neuphoria Therapeutics shares in Q1 2026, an estimated $76.3K.
  • Neuphoria Therapeutics made up 0.05% of Shay Capital's portfolio in Q1 2026, its #230 holding.
  • Shay Capital first reported a position in Neuphoria Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Shay Capital's Neuphoria Therapeutics position peaked at $656K in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Shay Capital's 13F filing for Q1 2026, filed 15 May 2026.